Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project
Open accessAbstract
Background —Previous trials have had insufficient numbers of coronary events to address definitively the effect of lipid-modifying therapy on coronary heart disease in subgroups of patients with varying baseline characteristics. Methods and Results —The data from 3 large randomized trials with pravastatin 40 mg were pooled and analyzed with the use of a prospectively defined protocol. Included were 19 768 patients, 102 559 person-years of follow-up, 2194 primary end points (coronary death or nonfatal myocardial infarction), and 3717 expanded end points (primary end point, CABG, or PTCA). Pravastatin significantly reduced relative risk in younger (<65 years) and older (≥65 years) patients, men and women, smokers and nonsmokers, and patients with or without diabetes or hypertension. The relative effect was smaller, but absolute risk reduction was similar in patients with hypertension compared with those without hypertension. Relative risk reduction was significant in predefined categories of baseline lipid concentrations. Tests for interaction were not significant between relative risk reduction and baseline total cholesterol (5% to 95% range 177 to 297 mg/dL, 4.6 to 7.7 mmol/L), HDL cholesterol (27 to 58 mg/dL, 0.7 to 1.5 mmol/L), and triglyceride (74 to 302 mg/dL, 0.8 to 3.4 mmol/L) concentrations, analyzed as continuous variables. However, for LDL cholesterol, the probability values for interaction were 0.068 for the prespecified primary end point and 0.019 for the expanded end point. Relative risk reduction was similar throughout most of the baseline LDL cholesterol range (125 to 212 mg/dL, 3.2 to 5.5 mmol/L) with the possible exception of the lowest quintile of CARE/LIPID (<125 mg/dL) (relative risk reduction 5%, 95% CI 19% to −12%). Conclusions —Pravastatin treatment is effective in reducing coronary heart disease events in patients with high or low risk factor status and across a wide range of pretreatment lipid concentrations.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Reductions in plasma triglyceride are associated with reduction in the risk of atherosclerotic cardiovascular disease events after adjustment for statin-induced LDL-C lowering.
“There is also evidence that reductions in plasma TG are associated with reduction in the risk of ASCVD events after adjustment for statin-induced LDL-C lowering.39–42”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McCullagh, P., & Nelder, J. A. (1989) · doi:10.1007/978-1-4899-3242-6 · Cited by 16,836 · see citing works
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449 · see citing works
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · see citing works
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261 · see citing works
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453 · see citing works
Generalized linear models. 2nd ed.
McCullagh, P., & Nelder, J. (1993) · Journal of the American Statistical Association · doi:10.2307/2290358 · Cited by 1,581 · see citing works
National Cholesterol Education Program
Lenfant, C. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400060019005 · Cited by 1,184 · see citing works
The National Cholesterol Education Program
Cleeman, J. I. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30638-3 · Cited by 711 · see citing works
Carlson, L. A., & Rosenhamer, G. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15891.x · Cited by 685 · see citing works
Pedersen, T. R., OLSSON, A. G., Færgeman, O., KJEKSHUS, J. K., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T. H., Þorgeirsson, G., Pyörälà, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.15.1453 · Cited by 618 · see citing works
Gotto, A. M., Whitney, E. J., Stein, E. A., Shapiro, D. R., Clearfield, M. B., Weis, S. E., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 562 · see citing works
Miettinen, T. A., Pyörälä, K., Olsson, A. G., Musliner, T. A., Cook, T. J., Faergeman, O., Berg, K., Pedersen, T., Kjekshus, J., & Group, F. T. S. S. S. (1997) · Circulation · doi:10.1161/01.cir.96.12.4211 · Cited by 508 · see citing works
Rubinstein, A. (1995) · PubMed · Cited by 92 · see citing works
Influence of baseline lipids on effectiveness of pravastatin in the CARE trial
Pfeffer, M. A., Sacks, F. M., Moyé, L. A., East, C. A., Goldman, S. M., Nash, D. T., Rouleau, J. R., Rouleau, J. L., Sussex, B. A., Théroux, P., et al. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00522-1 · Cited by 89 · see citing works
Self-citationThe PPP Project Investigators (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80259-8 · Cited by 44 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- The PPP Project Investigators. Design, rationale, and baseline character- istics of the Prospective Pravastatin Pooling (PPP) Project. Am J Cardiol. 1995;76:899 -905.
- Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation. 1997;96:4211-4218.
Cited by
Sorted by citations
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378 · see citing works
Self-citationHDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610 · see citing works
Grundy, S. M., Cleeman, J. I., Bairey Merz, C. N., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.001 · Cited by 1,550 · see citing works
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979 · see citing works
Self-citationSubgroup analysis in randomised controlled trials: importance, indications, and interpretation
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17709-5 · Cited by 942 · see citing works
Guidelines for improving the care of the older person with diabetes mellitus
California Healthcare Foundation/American Geriatrics Society, C. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.51.5s.1.x · Cited by 651 · see citing works
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586 · see citing works
Sampson, U. K., Fazio, S., & Linton, M. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0219-7 · Cited by 439 · see citing works
van der Steeg, W. A., Holme, I., Boekholdt, S. M., Larsen, M. L., Lindahl, C., Stroes, E. S. G., Tikkanen, M. J., Wareham, N. J., Faergeman, O., Olsson, A. G., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.060 · Cited by 374 · see citing works
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197 · see citing works
Low density lipoprotein size, pravastatin treatment, and coronary events.
Campos, H. (2001) · JAMA · doi:10.1001/jama.286.12.1468 · Cited by 132 · see citing works
Jenkins, D. J. A., Kendall, C. W. C., Marchie, A., Faulkner, D., Vidgen, E., Lapsley, K. G., Trautwein, E. A., Parker, T. L., Josse, R. G., Leiter, L. A., et al. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00260-9 · Cited by 131 · see citing works
Differential metabolic effects of distinct statins
Koh, K. K., Sakuma, I., & Quon, M. J. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.036 · Cited by 130 · see citing works
Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients
Koh, K. K., Quon, M. J., Han, S. H., Lee, Y., Kim, S. J., Park, J. B., & Shin, E. K. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.09.021 · Cited by 119 · see citing works
Koh, K. K., Quon, M. J., Han, S. H., Lee, Y., Ahn, J. Y., Kim, S. J., Koh, Y., & Shin, E. K. (2008) · Diabetes Care · doi:10.2337/dc07-2199 · Cited by 114 · see citing works
Imano, H., Noda, H., Kitamura, A., Sato, S., Kiyama, M., Sankai, T., Ohira, T., Nakamura, M., Yamagishi, K., Ikeda, A., et al. (2011) · Preventive Medicine · doi:10.1016/j.ypmed.2011.02.019 · Cited by 97 · see citing works
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83 · see citing works
The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk
Corsini, A. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1026132412074 · Cited by 82 · see citing works
Sacks, F. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.073 · Cited by 50 · see citing works
Self-citationNoda, H., Iso, H., Irie, F., Sairenchi, T., Ohtaka, E., & Ohta, H. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02183.x · Cited by 48 · see citing works
High-risk elderly patients PROSPER from cholesterol-lowering therapy
Collins, R., & Armitage, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11650-3 · Cited by 42 · see citing works
The epidemiological concept of residual risk
Vanuzzo, D. (2011) · Internal and Emergency Medicine · doi:10.1007/s11739-011-0669-5 · Cited by 41 · see citing works
- Authors
- Sacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C. M., Keech, A., Packard, C., Simes, J., Byington, R., & Furberg, C. D.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Brigham and Women’s Hospital (F.M.S., E.B.), Harvard Medical School (F.M.S., E.B.), and Harvard School of Public Health (F.M.S.), Boston, Mass; National Heart Foundation (A.M.T.), Melbourne, Australia; University of Glasgow (J.S., S.C., C.P.), Glasgow, Scotland; University of Texas School of Public Health, Houston (C.M.H.); University of Sydney (A.K., J.S.), Sydney, Australia; and Wake Forest University (R.B., C.D.F.), Winston Salem, NC.
- Venue
- Circulation
- Published
- 2000-10-17
- Volume
- 102
- Issue
- 16
- Pages
- 1893-1900
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2072734670
- Cited by
- 388
- References
- 17
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 2 · 2018: 6 · 2017: 8 · 2016: 6 · 2015: 6 · 2014: 11 · 2013: 10 · 2012: 10
- FWCI
- 39.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Wake Forest University
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Keywords
- pravastatin, coronary artery disease, lipid therapy, subgroup analysis, LDL cholesterol, HDL cholesterol, triglycerides, hypertension, diabetes mellitus, smoking, age and sex differences, myocardial infarction, coronary death, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, pooled analysis
- MeSH terms
- Aged, Anticholesteremic Agents, Cholesterol, Coronary Disease, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Prospective Studies, Risk Factors, Triglycerides, Treatment Outcome, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
